AmyriAD Therapeutics Acquires Recognify Life Sciences and RL-007

Pelago Bioscience Acquires RG Discovery

June 15, 2026

Healthcare Services

Pelago Bioscience, a cell-based target engagement contract research organization (CRO), has acquired RG Discovery to create an integrated drug discovery platform spanning biology and medicinal chemistry. The combination is intended to support customers across the full DMTA (design-make-test-analyze) cycle with a single specialist partner, reducing workflow handoffs from hit identification through lead optimization.

Juvenescence Acquires AI Drug-Discovery Company Ro5

June 5, 2025

Biotechnology

Juvenescence Limited has acquired Ro5 Inc., an AI-driven drug discovery company, to integrate Ro5's Biomedical Knowledge Graph and AI chemistry platform into Juvenescence's R&D operations. The deal strengthens Juvenescence's machine-learning drug discovery capabilities and supports its strategic partnership with Abu Dhabi-based M42 to accelerate the development of therapeutics targeting age-related diseases.

MediSpend Acquires Real Life Sciences

January 27, 2025

Cloud & SaaS

MediSpend, a Susquehanna Growth Equity‑backed life sciences technology company, has acquired Real Life Sciences (RLS), a provider of advanced anonymization and redaction solutions for clinical trial data. The deal expands MediSpend's Governance, Risk and Compliance (GRC) capabilities—adding RLS Protect SaaS and expert anonymization services to support pharma, biotech and CRO clients with regulatory disclosure and participant privacy.

Recognize Acquires Majority Stake in Sprout

January 9, 2025

IT Services

Recognize, a private equity firm focused on digital services, has made a majority investment in IT asset disposition (ITAD) provider Sprout. New Capital Partners will remain a minority investor; Recognize plans to invest in Sprout’s technology, expand solutions, and pursue M&A to accelerate growth as demand for secure data destruction and hardware refresh cycles rises.

AbbVie Completes $1.4B Acquisition of Aliada Therapeutics

December 11, 2024

Biotechnology

AbbVie completed its $1.4 billion cash acquisition of RA Capital Management portfolio company Aliada Therapeutics. The deal adds ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in Phase 1 for Alzheimer’s disease, and Aliada’s blood-brain barrier (BBB)-crossing MODEL delivery platform to AbbVie’s neuroscience pipeline.

CenExel Clinical Research Acquires Advanced Memory Research Institute

August 19, 2021

Healthcare Services

CenExel Clinical Research, Inc. has acquired Advanced Memory Research Institute (CenExel AMRI), the largest Alzheimer's Disease clinical research site in the U.S. Northeast. The deal expands CenExel's CNS and Alzheimer's trial capabilities by integrating AMRI into its Centers of Excellence network; Provident Healthcare Partners served as exclusive sell-side financial advisor.